PHAT — Phathom Pharmaceuticals, Inc. stock price, charts and financials

Latest market price

8.45

-0.53-5.90%

Overview Short InterestFilings

PHATQT31Phathom Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

8.45-5.90%

News

Down 5.9% — Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT) (globenewswire.com).

Medium confidence

Loading chart...

Signal & projected range

Earnings big miss — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-2.12	Insider Own	32.62%	Shs Outstand	79.76M	Perf Week	-27.53%

Market Cap	673.94M	Forward P/E	9.15	EPS next Y	0.92	Insider Trans	0.00%	Shs Float	65.29M	Perf Month	-25.75%

Enterprise Value	494.94M	PEG	-	EPS next Q	0.11	Inst Own	-	Short Float	18.57%	Perf Quarter	-34.34%

Income	-157.00M	P/S	3.27	EPS this Y	63.52%	Inst Trans	-	Short Ratio	9.74	Perf Half Y	-38.81%

Sales	206.00M	P/B	-	EPS next Y	219.44%	ROA	-24.91%	Short Interest	12.12M	Perf YTD	-49.07%

Book/sh	-4.31	P/C	3.70	EPS next 5Y	-	ROE	21.14%	52W High	18.31 -53.85%	Perf Year	1.20%

Cash/sh	2.28	P/FCF	-	EPS past 3/5Y	-	ROIC	-23.36%	52W Low	8.03 5.23%	Perf 3Y	-42.94%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	82.92%	Volatility	8.31% 6.58%	Perf 5Y	-72.47%

Dividend TTM	-	EV/Sales	2.40	EPS Y/Y TTM	59.92%	Oper. Margin	-16.96%	ATR (14)	0.80	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	1.87	Sales Y/Y TTM	274.55%	Profit Margin	-34.00%	RSI (14)	30.90	Recom	2.11

Dividend Gr. 3/5Y	-	Current Ratio	1.92	EPS Q/Q	73.42%	SMA20	-22.78%	Beta	0.43	Target Price	22.00

Payout	0.00%	Debt/Eq	1.26	Sales Q/Q	85.00%	SMA50	-20.85%	Rel Volume	1.77	Prev Close	8.98

Employees	371	LT Debt/Eq	-0.48	Earnings	Oct 29	SMA200	-33.03%	Avg Volume	1.24M	Price	8.45

IPO Date	Oct 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-19.60% 1.42%	Net Debt/EBITDA	4.90	Volume	2,189,359	Change	-5.90%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-31-26	Reiterated	Craig-Hallum	Buy	$22 → $20
Jul-31-26	Reiterated	Guggenheim	Buy	$20 → $22
Jul-30-26	Reiterated	Needham	Buy	$26 → $22
Mar-27-26	Upgrade	Barclays	Equal Weight → Overweight	$16 → $18
Feb-26-26	Reiterated	Stifel Nicolaus		$24 → $28
Dec-11-25	Initiated	Raymond James	Strong Buy	$28
Dec-08-25	Initiated	Barclays	Equal Weight	$16
Oct-31-25	Reiterated	Craig-Hallum	Buy	$17 → $22
Oct-31-25	Reiterated	HC Wainwright & Co.	Buy	$28 → $26
Oct-30-25	Reiterated	Guggenheim	Buy	$18 → $20

Latest News

Aug-04-26

Aug-04-2610:09AM

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)globenewswire.com

Aug-03-26

Aug-03-2610:07AM

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)businesswire.com

Jul-31-26

Jul-31-2610:07AM

PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticalsprnewswire.com

Jul-30-26

Jul-30-2608:43PM

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcriptseekingalpha.com

05:34PM

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)prnewswire.com

03:05PM

Phathom Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com

01:23PM

Phathom Pharmaceuticals (PHAT) Falls After Cutting 2026 Revenue Guidance Despite Q2 BeatChartMill

11:30AM

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2zacks.com

06:59AM

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com

Jul-20-26

Jul-20-2608:00AM

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026globenewswire.com

Jun-23-26

Jun-23-2611:59AM

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)Yahoo

08:00AM

Phathom Pharmaceuticals Completes Patient Enrollment In Its Phase 2 pHalcon-EoE-201 Clinical Study Of VOQUEZNA Tablets To Treat Eosinophilic Esophagitis In AdultsBenzinga

Jun-17-26

Jun-17-2606:24AM

HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price TargetBenzinga

Company

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	206	175	55	1	0	0	0	0	0
Cost of Goods Sold Incl. D&A	31	23	8	0	1	1	0	0	0
Gross Profit	173	153	47	1	-1	-1	0	0	0
Selling, General and Administrative Excl. Other	239	280	291	118	100	62	27	7	1
Research and Development	31	33	34	50	71	72	98	99	0
Other Operating Expense	1	-1	0	0	1	1	0	0	0
Operating Income	-96	-160	-277	-167	-172	-135	-126	-106	-1
Interest Expense	66	68	72	42	27	7	5	4	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	5	7	15	8	2	-2	1	-145	0
Net Income Before Taxes	-157	-221	-334	-202	-198	-144	-129	-255	-1
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-157	-221	-334	-202	-198	-144	-129	-210	-1
Net Income From Continuing Operations	-157	-221	-334	-202	-198	-144	-129	-255	-1
Net Income	-157	-221	-334	-202	-198	-144	-129	-210	-1
EPS (Recurring)	-2.12	-3.03	-5.29	-3.93	-5.70	-4.00	-4.01	-8.48	-0.15
EPS (Basic, Before Extraordinaries)	-2.12	-3.03	-5.29	-3.93	-5.70	-4.00	-4.01	-8.48	-0.15
EPS (Diluted)	-2.12	-3.03	-5.29	-3.93	-5.70	-4.00	-4.01	-8.48	-0.15
EBITDA	-91	-152	-262	-159	-170	-137	-124	-251	0
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	3.36	6.92	9.30	465.63	—	—	—	—	—
Gross Margin	83.98	87.43	85.45	100.00	—	—	—	—	—
Operating Margin	-46.60	-91.43	-503.64	-16,700.00	—	—	—	—	—
Net Margin	-76.21	-126.29	-607.27	-20,200.00	—	—	—	—	—
Shares Outstanding	82	73	63	51	39	37	33	25	9
Market Capitalization	693	1,211	512	466	438	728	1,096	779	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parikh Asit	Director	May 20 '26	Option Exercise	4.95	17,500	86,625	52,122	May 21
Parikh Asit	Director	Jan 13 '26	Option Exercise	10.30	8,750	90,125	131,000	Jan 15
Parikh Asit	Director	Dec 19 '25	Option Exercise	10.30	8,750	90,125	122,250	Dec 23
Basta Steven L	President and CEO	Nov 28 '25	Option Exercise	0.00	90,000	0	131,625	Dec 02
Breedlove Robert Charles	Principal Accounting Officer	Nov 03 '25	Sale	13.51	524	7,079	47,407	Nov 05
Basta Steven L	President and CEO	Sep 25 '25	Option Exercise	0.00	90,000	0	90,000	Sep 26
Breedlove Robert Charles	Principal Accounting Officer	Sep 05 '25	Sale	12.09	461	5,573	47,931	Sep 09
Breedlove Robert Charles	Principal Accounting Officer	Jul 16 '25	Sale	8.36	1,692	14,152	48,392	Jul 18
Topper James N	Director	May 21 '25	Buy	3.86	3,780	14,609	59,403	May 23
Topper James N	Director	May 14 '25	Buy	3.32	6,300	20,919	55,623	May 15
Topper James N	Director	May 13 '25	Buy	3.16	1,120	3,543	49,323	May 15
Topper James N	Director	May 12 '25	Buy	3.04	12,601	38,301	48,203	May 13
Topper James N	Director	May 09 '25	Buy	3.22	35,602	114,616	35,602	May 13
Parikh Asit	Director	May 07 '25	Buy	2.40	5,000	11,985	95,500	May 08
Parikh Asit	Director	May 06 '25	Buy	2.60	5,000	13,000	90,500	May 08

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.